Distributed through LillyDirect®'s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesityINDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand. The single-dose vials are priced at a 50% or grea ...

Prior to an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and look to tap into stocks that are of high quality.In this regard, we ran a screener that yielded Norwegian Cruise Line Holdings Ltd. (NCLH) , Eli Lilly (LLY) , The Progressive (PGR) and Fortinet (FTNT) as the likely winners on the earnings beat potential.Why is a Positive Earnings Surprise Important?Historically, stocks of companies with ...

Eli Lilly and Company TodayLLYEli Lilly and Company$945.17 -7.57 (-0.79%) 52-Week Range$516.57▼$972.53Dividend Yield0.55%P/E Ratio139.20Price Target$956.88Add to WatchlistEli Lilly and Co. NYSE: LLY is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, known as Mounjaro for type 2 diabetes, and Zepbound for obesity. Its stock is trading back near its all-time high at $972.52. Its market capitalization hovers around the $857 billion mark. The company has many growth ...

The drugmaker looks unstoppable.To paraphrase a Shakespeare quote, bad news and misfortune tend to come in groups. But that may also apply to good news. Just ask Eli Lilly (LLY -0.15%), a pharmaceutical company that has been flying on all cylinders. The drugmaker continues to impress investors with exceptional financial results, impressive regulatory wins, and exciting clinical progress.Much of the company's recent success has to do with tirzepatide, a medicine for diabetes (marketed as Mounjaro) and for ob ...

The S&P 500's top three at year-end could look a little different than they do now.You've likely heard some form of the disclaimer, "Past performance is no guarantee of future results." And the statement is true. However, I'd add something to the disclaimer: "But a big head start is nearly always a good thing."Several large-cap stocks have a big head start that could enable them to finish the year strong. I predict these will be the three best-performing S&P 500 (^GSPC 1.15%) stocks of 2024.1. NvidiaNvidia ...

Core Viewpoint - Eli Lilly's current high valuation may be justified by its rapid earnings growth, particularly driven by its successful diabetes drug Mounjaro and its new weight-loss treatment Zepbound, which could become the company's top seller in the near future [1][2]. Financial Performance - For the three-month period ending June 30, Eli Lilly's revenue increased by 36% year over year to $11.3 billion, largely due to the growth of Mounjaro and Zepbound [2]. - The company's operating income rose by 75% to $3.7 billion, despite incurring asset impairment and restructuring charges totaling $435 million during the period [2]. - Net income climbed by 68% to just under $3 billion, indicating strong earnings growth that supports the company's high valuation of $830 billion [2]. Growth Potential - Eli Lilly's stock trades at over 100 times its trailing profit, but the expected high earnings growth rate may mitigate concerns about its valuation [3]. - The company is positioned for significant future growth, which could make the stock appear less expensive than it currently seems [3]. Profitability Metrics - Eli Lilly's gross profit margin was 81% last quarter, with revenue rising by 36% while the cost of sales increased by only 20%, indicating operational efficiency [4]. - Maintaining high gross profit margins can lead to substantial earnings growth, as incremental sales growth will largely contribute to the bottom line [4]. Investment Outlook - Eli Lilly is expected to continue experiencing high sales growth, supported by impressive gross profit margins, which enhances confidence in its ability to increase earnings rapidly [6]. - The company faces challenges in meeting soaring product demand but is well-positioned to invest in operations to strengthen its manufacturing capabilities [6]. - With strong growth prospects and high margins, Eli Lilly stock is considered an excellent long-term investment opportunity [6].

Company Overview - Eli Lilly's shares rose over 3% following the long-term data release from the SURMOUNT-1 study, which demonstrated a 94% reduction in the risk of developing type 2 diabetes (T2D) in obese or overweight adults with pre-diabetes after three years of treatment with tirzepatide [1][2] - Tirzepatide is the active ingredient in Eli Lilly's obesity drug Zepbound and diabetes drug Mounjaro, showing significant average weight reductions of 15.4% at 5mg, 19.9% at 10mg, and 22.9% at 15mg compared to 2.1% for placebo over a 176-week treatment period [1][2] Market Performance - Following the announcement of the study results, Eli Lilly's shares reached an all-time high of $967 on August 20, with a year-to-date increase of 63.0%, outperforming the industry average rise of 24.7% [3] - The SURMOUNT-1 study results contribute to the growing list of health benefits associated with tirzepatide, which may lead to increased sales and potential Medicare coverage for obesity medications [3] Industry Insights - The GLP-1 drug segment is gaining popularity for treating multiple cardiometabolic diseases, with significant weight loss and reduced cardiovascular risks [5] - The obesity market in the U.S. is projected to reach $130 billion by the end of the decade, prompting Eli Lilly and competitors like Novo Nordisk to invest heavily in production capacity and explore new obesity drug candidates [7] Competitive Landscape - Novo Nordisk has also seen substantial stock growth, with a 415% increase over the past five years, driven by the success of its semaglutide products, which compete directly with Eli Lilly's offerings [6] - Other companies, including Viking Therapeutics, Amgen, and Roche, are developing obesity drugs, indicating a competitive and rapidly evolving market landscape [7][8]

Core Insights - Eli Lilly shares reached a record high following the announcement of successful clinical trials for tirzepatide, which significantly reduced the risk of developing type 2 diabetes in patients [1][2] - Sales of Mounjaro and Zepbound exceeded Wall Street estimates, contributing to an 18% increase in Eli Lilly's shares this month [2] - The stock has been trading within a broadening wedge pattern since May last year, with key support and resistance levels identified [3] Price Levels Analysis - **Support Levels**: Key support is observed around $885, which aligns with the upward sloping 50-day moving average. A more significant support level is at $790, where buying interest may emerge [4] - **Resistance Levels**: Initial resistance is noted at $950, close to the stock's record close from mid-July. A further resistance level is at $1,000, where the stock may face challenges due to psychological factors and the upper trendline of the broadening wedge [5] Trading Activity - Recent trading saw Eli Lilly shares increase by 0.4% to $954.01 in premarket trading, with an all-time intraday high of $967 reached [3] - The recent price movements occurred on above-average volume, indicating renewed institutional interest despite a downward trend in share turnover over the past week [3]

Core Viewpoint - Eli Lilly's stock has increased by approximately 58% in 2024, with analysts believing there is potential for further growth, particularly due to the success of its drug tirzepatide [1] Group 1: Drug Performance - Tirzepatide, marketed as Mounjaro and Zepbound, has gained significant attention, with Q2 2024 sales reaching $4.3 billion, a 342% increase from $980 million in Q2 2023 [3] - In comparison, Novo Nordisk's semaglutide generated $6.9 billion in Q2 2024, reflecting a 26% year-over-year growth [3] - Tirzepatide's sales in Q2 2024 were 86% higher than in Q1 2024, indicating rapid market adoption [3] Group 2: Clinical Evidence and Growth Drivers - Clinical trials have shown that tirzepatide significantly reduces the risk of progressing to type 2 diabetes by 94% in pre-diabetic adults compared to placebo [4] - The drug has also demonstrated benefits for patients with obstructive sleep apnea and heart failure, reducing dangerous heart failure outcomes by 38% [4] - Tirzepatide currently accounts for 38% of Eli Lilly's total sales, with additional growth expected from the recently FDA-approved Kisunla for Alzheimer's disease [5] Group 3: Market Expectations and Valuation - Analysts project that tirzepatide could boost annual sales from $17.2 billion to over $50 billion at its peak, although the stock is currently trading at about 60 times forward-looking earnings expectations [6] - The potential for significant growth exists, but the market has already priced in high expectations, leading to concerns about valuation if unforeseen complications arise [7]

Group 1 - Eli Lilly's weight-loss drug, tirzepatide, significantly reduces the risk of developing type 2 diabetes by 94% in overweight patients with pre-diabetes compared to a placebo [1][2] - The treatment leads to sustained weight loss, with patients on the highest dose experiencing an average body weight decrease of 22.9% [1] - The study involved 1,032 adults over a three-year period [1] Group 2 - Obesity affects nearly 900 million adults globally, increasing the risk of complications like type 2 diabetes [2] - Eli Lilly's second-quarter earnings exceeded Wall Street expectations, with $11.3 billion in global revenue compared to the expected $9.92 billion [3] - Adjusted earnings per share were reported at $3.92, surpassing the anticipated $2.60 [3] Group 3 - Tirzepatide was first approved for type 2 diabetes treatment under the brand name Mounjaro in 2022 [4] - In November 2023, the injection was approved for adults with obesity or those with weight-related medical issues, marketed as Zepbound [4]